• Supernus Pharmaceuticals reported record revenues in 2025.
• The company completed the integration of Sage Therapeutics.
• New products ONAPGO for Parkinson's disease and ZURZUVAE for postpartum depression were launched.
• The business expanded into new therapeutic areas despite supply constraints.

For investors looking at NasdaqGM:SUPN, these company updates come with a stock that last closed at $54.73 and has returned 70.7% over the past year. Over 3 years the stock is up 37.5%, and over 5 years it is up 117.7%, providing context for how the market has reacted around Supernus Pharmaceuticals and its recent milestones.

The 2025 revenue record, acquisition integration and new product launches indicate that the business has been active on multiple fronts, from portfolio development to operations. As Supernus Pharmaceuticals continues its involvement in Parkinson's disease and postpartum depression treatment areas, investors may want to monitor how ONAPGO and ZURZUVAE adoption, along with ongoing supply management, are reflected in future company updates.

Stay updated on the most important news stories for Supernus Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Supernus Pharmaceuticals.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$54.73 versus a consensus target of US$63.17, the price is about 13% below analyst expectations.
• ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading 72.4% below the Simply Wall St fair value estimate.
• ✅ Recent Momentum: A 30 day return of 11.8% suggests the market has recently reacted positively.

There is only one way to know the right time to buy, sell or hold Supernus Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Supernus Pharmaceuticals's Fair Value.

Key Considerations

• 📊 Record 2025 revenues, the Sage Therapeutics integration and new CNS launches put execution in Parkinson's disease and postpartum depression at the center of the story.
• 📊 Keep an eye on ONAPGO and ZURZUVAE uptake, supply constraints, and whether margins move closer to the Pharmaceuticals industry average profit margin of 21.9%.
• ⚠️ Current net income of US$38.6m loss and a negative P/E of 81.6 highlight that profitability is not yet aligned with the high growth expectations.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Supernus Pharmaceuticals analysis. Alternatively, you can check out the community page for Supernus Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.